HilleVax (NASDAQ:HLVX) Stock Rating Lowered by Leerink Partnrs

HilleVax (NASDAQ:HLVX) was downgraded by stock analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.

Other analysts have also issued research reports about the stock. Stifel Nicolaus lowered shares of HilleVax from a “buy” rating to a “hold” rating and lowered their price objective for the company from $34.00 to $3.00 in a research note on Tuesday. SVB Leerink downgraded HilleVax from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $28.00 to $2.00 in a report on Tuesday. Guggenheim cut HilleVax from a “buy” rating to a “neutral” rating in a report on Monday. HC Wainwright restated a “neutral” rating and set a $2.00 price target (down previously from $28.00) on shares of HilleVax in a research note on Tuesday. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 target price (down previously from $24.00) on shares of HilleVax in a research note on Monday. Six research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.20.

HilleVax Trading Down 3.6 %

HLVX opened at $1.63 on Tuesday. The company has a market cap of $81.04 million, a P/E ratio of -0.49 and a beta of 0.78. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. The company’s 50 day moving average is $13.04 and its 200-day moving average is $14.59. HilleVax has a 1-year low of $1.55 and a 1-year high of $20.22.

HilleVax (NASDAQ:HLVX) last posted its earnings results on Thursday, May 9th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). Equities research analysts predict that HilleVax will post -3.14 earnings per share for the current fiscal year.

Insider Buying and Selling at HilleVax

In other news, Director Aditya Kohli sold 6,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the sale, the director now owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 12,898 shares of company stock worth $193,766 over the last 90 days. Corporate insiders own 71.10% of the company’s stock.

Institutional Investors Weigh In On HilleVax

Large investors have recently made changes to their positions in the business. Tidal Investments LLC bought a new stake in HilleVax during the first quarter worth about $207,000. EntryPoint Capital LLC purchased a new position in shares of HilleVax during the first quarter valued at approximately $80,000. Catalys Pacific LLC bought a new stake in shares of HilleVax in the 4th quarter worth approximately $21,009,000. Franklin Resources Inc. boosted its position in shares of HilleVax by 4.1% in the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock worth $29,635,000 after purchasing an additional 71,938 shares in the last quarter. Finally, Swiss National Bank grew its stake in shares of HilleVax by 22.4% in the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after buying an additional 7,000 shares during the last quarter. 86.42% of the stock is currently owned by institutional investors.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.